Oral squamous cell carcinoma-derived EVs promote tumor progression by regulating inflammatory cytokines and the IL-17A-induced signaling pathway.

Abstract

BACKGROUND:

Inflammatory cytokines in the tumor microenvironment (TME) contribute to tumor growth, proliferation, and invasion, and tumor-derived extracellular vesicles (EVs) act as critical "messengers" of communication in the tumor microenvironment. The effects of EVs derived from oral squamous cell carcinoma (OSCC) cells on tumor progression and the inflammatory microenvironment are still unclear. Our study aims to investigate the role of OSCC-derived EVs in tumor progression, the imbalanced TME, and immunosuppression and their effect on the IL-17A-induced signaling pathway.

METHODS:

EVs were isolated from the supernatant of a mouse OSCC cell line, SCC7. The effects of SCC7-EVs and the EV release-specific inhibitor GW4869 on the proliferation and migration of SCC7 cells were investigated in vitro by using CCK-8 and scratch wound healing assays. RT-qPCR and ELISA were performed to examine the alterations in cytokine levels. Then, a mouse xenograft model of OSCC was established by submucosal injection of SCC7 cells with or without SCC7-EV and GW4869 treatment. The effects of GW4869 and SCC7-EVs on xenograft tumor proliferation and invasion were investigated by tumor volume determination and histopathological examination. ELISA was used to investigate the changes in serum cytokine levels. Immunohistochemistry was adopted to analyze the alterations in the levels of inflammatory cytokines, immune factors, and crucial molecules in the IL-17A signaling pathway.

RESULTS:

SCC7-derived EVs increased the supernatant and serum levels of IL-17A, IL-10, IL-1β, and PD-L1, while GW4869 decreased those of TNF-α and IFN-γ. SCC7-EV treatment significantly increased xenograft tumor growth and invasion in mice but resulted in little liquefactive necrosis in tumors. However, GW4869 treatment significantly inhibited xenograft tumor growth but resulted in more liquefactive necrosis. SCC7-derived EVs decreased the expression level of PTPN2, suppressing the immune responses of CD8 + T cells in vivo. Moreover, SCC7-EV treatment significantly enhanced the tumor expression levels of crucial molecules in the IL-17A pathway, including IL-17A, TRAF6 and c-FOS, whereas GW4869 treatment significantly reduced those levels in tumor tissues.

CONCLUSION:

Our results indicated that OSCC-derived EVs can promote tumor progression by altering the TME, causing an inflammatory cytokine imbalance, inducing immunosuppression, and contributing to overactivation of the IL-17A-induced signaling pathway. Our study might provide novel insights into the role of OSCC-derived EVs in tumor biological behavior and immune dysregulation.

• Authors: Ruowei Li, Yifan Zhou, Miaomiao Zhang, Ruiqi Xie, Ning Duan, Hong Liu, Yao Qin, Jingjing Ma, Zhiyuan Li, Pei Ye, Wenmei Wang, Xiang Wang
• Journal: International immunopharmacology (Int Immunopharmacol) Vol. 118 Pg. 110094 (May 2023) ISSN: 1878-1705 [Electronic] Netherlands
• PMID: 37030119 (Publication Type: Journal Article)
• Copyright: Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Chemical References

• Cytokines
• GW 4869
• Interleukin-17
• Protein Tyrosine Phosphatase, Non-Receptor Type 2
• Ptpn2 protein, mouse
• Il17a protein, mouse

Topics

• Animals
• Humans
• Mice
• Carcinoma, Squamous Cell (metabolism)
• Cell Line, Tumor
• Cytokines (metabolism)
• Disease Models, Animal
• Extracellular Vesicles (metabolism)
• Head and Neck Neoplasms (pathology)
• Interleukin-17 (metabolism)
• Mouth Neoplasms (metabolism, pathology)
• Necrosis (pathology)
• Protein Tyrosine Phosphatase, Non-Receptor Type 2 (metabolism)
• Signal Transduction
• Squamous Cell Carcinoma of Head and Neck (pathology)
• Tumor Microenvironment